We are an emerging leader in the global cannabis industry.

Emerald Health Therapeutics is a Health Canada Licensed Producer of medical cannabis. A vertically integrated, seed-to-sale enterprise, Emerald has combined core competencies from decades of experience in pharmaceutical innovation with large-scale agriculture expertise. Our ambition is to be at the forefront of developing knowledge and products that provide wellness and health benefits from cannabis.

Venture50 2018

Emerald believes the next wave of adult users and medical consumers of cannabis products will demand consistent dosing and alternative methods of consumption with safety assured through GMP compliant production.

— Executive Chairman, Avtar Dhillon, MD

GROWTH

Emerald’s multi-phase expansion plan is timed for massive scaling to meet anticipated demand from the legalized adult-use recreational cannabis market, slated for October 17, 2018. In our 50%-owned Pure Sunfarms partnership, to date, 225,000 square feet of a 1.1 million square foot greenhouse has been converted and approved by Health Canada for cannabis production. The facility is scheduled for completion in the fall of 2018. Emerald recently acquired Agro-Biotech, a Licenced Producer in Saint-Eustache, Quebec. The 75,000 square foot indoor facility will supply high-quality and unique cannabis products for the Quebecois and eastern Canadian markets, where over half of Canada’s population resides. Health Canada has approved a modular expansion project on a 32-acre site in Metro-Vancouver, for a 500,000 square foot hybrid indoor and greenhouse growing space. This facility will also house extraction, and other processing capabilities as Emerald pursues value-added downstream product development.

PRODUCTS

With an industry-leading pool of cannabis genetics and a strong focus on product innovation backed by decades of rigorous pharmaceutical industry R&D and clinical development, Emerald is putting in place the components for creating consistent high-value downstream products for both the recreational and medical markets. We believe cannabinoid medicines present an unparalleled opportunity for use as therapeutic alternatives to a host of conventional pharmaceutical medicines that are typically much more toxic, potentially less efficacious, and often highly addictive. Emerald expects that proprietary intellectual property created through its product innovation efforts will be beneficial in creating competitive advantages as well as consumer confidence and product preference for a growing new wave of adult users.

Learn more about Emerald’s Products.

PEOPLE

Emerald’s leadership is among the industry’s most experienced in pharmaceutical drug discovery, development, production, and distribution. Team members have extensive hands-on experience in clinical research, GMP production practices, regulatory approval processes, and intellectual property creation.

Meet the Team

Get in touch with us…

Toll Free Tel: 1.800.757.3536

The total market size potential of recreational marijuana in Canada is more than $22.6 billion.

— Source: Deloitte, Recreational Marijuana: Insights and Opportunities